Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

RANI THERAPEUTICS HOLDINGS, INC.

(RANI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/20/2022 01/21/2022 01/24/2022 01/25/2022 01/26/2022 Date
21.04(c) 18.88(c) 18.37(c) 19.35(c) 20.98 Last
27 711 53 393 44 629 16 161 5 304 Volume
-4.10% -10.27% -2.70% +5.33% +8.42% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2,92 M - -
Net income 2021 -52,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -17,5x
Yield 2021 -
Sales 2022 1,15 M - -
Net income 2022 -60,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -15,3x
Yield 2022 -
Capitalization 381 M 381 M -
Capi. / Sales 2021 131x
Capi. / Sales 2022 332x
Nbr of Employees 91
Free-Float -
More Financials
Company
Rani Therapeutics Holdings, Inc is a clinical stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. It develops the RaniPill capsule, which replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill that is designed to administer a precise therapeutic dose of medication upon deployment in the... 
More about the company
All news about RANI THERAPEUTICS HOLDINGS, INC.
01/07Rani Therapeutics Appoints Lisa Rometty to Board of Directors
AQ
01/05RANI THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/05Rani Therapeutics Holdings, Inc. Announces Appointment of Lisa Rometty as Director
CI
2021RANI THERAPEUTICS HOLDINGS, INC.(NAS : RANI) added to S&P Global BMI Index
CI
2021RANI THERAPEUTICS HOLDINGS, INC.(NAS : RANI) added to NASDAQ Biotechnology Index
CI
2021RANI THERAPEUTICS : Reports Third Quarter 2021 Financial Results, Provides Corporate Updat..
PU
2021RANI THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Con..
AQ
2021Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Upda..
GL
2021Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Upda..
GL
2021RANI THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Rani Therapeutics Appoints Lyn Baranowski to Board of Directors
AQ
2021Rani Therapeutics Holdings, Inc. Appoints Lyn Baranowski to Board of Directors
CI
2021Rani Therapeutics to Participate in a Fireside Chat at the Stifel 2021 Virtual Healthca..
AQ
2021RANI THERAPEUTICS HOLDINGS, INC. : Regulation FD Disclosure, Financial Statements and Exhi..
AQ
2021Rani Therapeutics to Present at Cantor Fitzgerald Virtual Global Healthcare Conference
GL
More news
News in other languages on RANI THERAPEUTICS HOLDINGS, INC.
01/05Rani Therapeutics Holdings, Inc. annonce la nomination de Lisa Rometty au poste de dire..
2021Rani Therapeutics lève 84,3 millions de dollars en produit brut de son introduction en ..
More news
Analyst Recommendations on RANI THERAPEUTICS HOLDINGS, INC.
More recommendations
Chart RANI THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Rani Therapeutics Holdings, Inc. Technical Analysis Chart | RANI | US7530181004 | MarketScreener
Technical analysis trends RANI THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 19,35 $
Average target price 28,40 $
Spread / Average Target 46,8%
EPS Revisions
Managers and Directors
Talat Imran Chief Executive Officer & Director
Svai S. Sanford Chief Financial Officer
Mir A. Imran Executive Chairman
Mir Hashim Chief Scientific Officer
Dennis Arthur Ausiello Independent Director
Sector and Competitors
1st jan.Capi. (M$)
RANI THERAPEUTICS HOLDINGS, INC.18.35%381
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
SEAGEN INC.-19.08%22 875
ICON PUBLIC LIMITED COMPANY-19.15%20 381